Loading...

Bristow, Robert E

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentObstetrics and Gynecology
Address1001 Health Sciences Road
CA 92697-3950
Phone(714) 456-5968
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Spatiotemporal Analysis of Disparities in Ovarian Cancer Treatment and Survival
    NIH/NIMHD R01MD009697Apr 12, 2016 - Dec 31, 2020
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lim MC, Won YJ, Lim J, Salehi T, Yoo CW, Bristow R. Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study. BMC Cancer. 2018 Aug 08; 18(1):800. PMID: 30089478.
      View in: PubMed
    2. Pfaendler KS, Chang J, Ziogas A, Bristow R, Penner KR. Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California. Obstet Gynecol. 2018 May; 131(5):899-908. PMID: 29630020.
      View in: PubMed
    3. Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT. The Future of Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):329-340. PMID: 29126306.
      View in: PubMed
    4. Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow R, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Mar 15. PMID: 29550184.
      View in: PubMed
    5. Lim MC, Won YJ, Lim J, Seo SS, Kang S, Yoo CW, Kim JY, Oh JH, Bristow R, Park SY. Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae. J Cancer Res Clin Oncol. 2018 May; 144(5):845-854. PMID: 29445866.
      View in: PubMed
    6. Ricci S, Tergas AI, Long Roche K, Fairbairn MG, Levinson KL, Dowdy SC, Bristow R, Lopez M, Slaughter K, Moore K, Fader AN. Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. Gynecol Oncol Rep. 2017 Nov; 22:100-104. PMID: 29201989.
      View in: PubMed
    7. Nasser S, Kyrgiou M, Krell J, Haidopoulos D, Bristow R, Fotopoulou C. A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries. Ann Surg Oncol. 2017 Nov; 24(12):3700-3705. PMID: 28861808.
      View in: PubMed
    8. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 Feb; 73(2):178-211. PMID: 28655541.
      View in: PubMed
    9. Leiserowitz GS, Lin JF, Tergas AI, Cliby WA, Bristow R. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. Int J Gynecol Cancer. 2017 05; 27(4):675-683. PMID: 28328580.
      View in: PubMed
    10. Vieira VM, Villanueva C, Chang J, Ziogas A, Bristow R. Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. Environ Res. 2017 07; 156:388-393. PMID: 28395243.
      View in: PubMed
    11. Salani R, Khanna N, Frimer M, Bristow R, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017 07; 146(1):3-10. PMID: 28372871.
      View in: PubMed
    12. Weinberg BA, Gowen K, Lee TK, Ou SI, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist. 2017 02; 22(2):152-157. PMID: 28193735.
      View in: PubMed
    13. Serna-Gallegos T, Gallegos N, Bristow R. Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma. Gynecol Oncol Rep. 2017 Feb; 19:31-33. PMID: 28050597.
      View in: PubMed
    14. Kim HS, Bristow R, Chang SJ. Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis. Gynecol Oncol. 2016 Dec; 143(3):688-689. PMID: 27743737.
      View in: PubMed
    15. Smith AD, Truong M, Bristow R, Yip P, Milosevic MF, Joshua AM. The Utility of Serum CA9 for Prognostication in Prostate Cancer. Anticancer Res. 2016 09; 36(9):4489-92. PMID: 27630286.
      View in: PubMed
    16. Sawyer BT, LaFargue CJ, Bristow R. Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer. Gynecol Oncol. 2016 Aug; 142(2):378. PMID: 27264212.
      View in: PubMed
    17. Suh DH, Kim HS, Chang SJ, Bristow R. Surgical management of recurrent ovarian cancer. Gynecol Oncol. 2016 08; 142(2):357-67. PMID: 27130407.
      View in: PubMed
    18. Wallace SK, Lin JF, Cliby WA, Leiserowitz GS, Tergas AI, Bristow R. Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study. J Natl Compr Canc Netw. 2016 05; 14(5):539-50. PMID: 27160232.
      View in: PubMed
    19. Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, Clarke-Pearson D, Goff B, Bristow R, Taylor HS, Farias-Eisner R, Fader AN, Maxwell GL, Goodwin SC, Love S, Gibbons WE, Foshag LJ, Leppert PC, Norsigian J, Nager CW, Johnson T, Guzick DS, As-Sanie S, Paulson RJ, Farquhar C, Bradley L, Scheib SA, Bilchik AJ, Rice LW, Dionne C, Jacoby A, Ascher-Walsh C, Kilpatrick SJ, Adamson GD, Siedhoff M, Israel R, Paraiso MF, Frumovitz MM, Lurain JR, Al-Hendy A, Benrubi GI, Raman SS, Kho RM, Anderson TL, Reynolds RK, DeLancey J. An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. J Minim Invasive Gynecol. 2016 Mar-Apr; 23(3):303-8. PMID: 26773577.
      View in: PubMed
    20. Fader AN, Weise RM, Sinno AK, Tanner EJ, Borah BJ, Moriarty JP, Bristow R, Makary MA, Pronovost PJ, Hutfless S, Dowdy SC. Utilization of Minimally Invasive Surgery in Endometrial Cancer Care: A Quality and Cost Disparity. Obstet Gynecol. 2016 Jan; 127(1):91-100. PMID: 26646127.
      View in: PubMed
    21. Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, Hermanns T, Chung P, Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MA, Zlotta AR, Sridhar SS, Kulkarni GS. The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Can Urol Assoc J. 2016 Jan-Feb; 10(1-2):25-30. PMID: 26977202; PMCID: PMC4771554.
    22. Galvan-Turner VB, Chang J, Ziogas A, Bristow R. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer. Gynecol Oncol. 2015 Dec; 139(3):495-9. PMID: 26387962.
      View in: PubMed
    23. Tseng JH, Roche KL, Jernigan AM, Salani R, Bristow R, Fader AN. Lifestyle and Weight Management Counseling in Uterine Cancer Survivors: A Study of the Uterine Cancer Action Network. Int J Gynecol Cancer. 2015 Sep; 25(7):1285-91. PMID: 25966932.
      View in: PubMed
    24. Aletti GD, Bristow R, Chi D, Cliby WA. There Is Nothing New Under the Sun. J Clin Oncol. 2015 Oct 20; 33(30):3520. PMID: 26304883.
      View in: PubMed
    25. Wang E, Brueseke T, Bristow R. Finding a needle in a haystack: Ultrasound guided extraction of a sewing needle from the perineum. Case Rep Womens Health. 2015 Jul; 7:3-4. PMID: 29629307.
      View in: PubMed
    26. Chang SJ, Bristow R, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015 Oct; 26(4):336-42. PMID: 26197773; PMCID: PMC4620371.
    27. Cohn DE, Havrilesky LJ, Osann K, Lipscomb J, Hsieh S, Walker JL, Wright AA, Alvarez RD, Karlan BY, Bristow R, DiSilvestro PA, Wakabayashi MT, Morgan R, Mukamel DB, Wenzel L. Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecol Oncol. 2015 Sep; 138(3):712-6. PMID: 26177553; PMCID: PMC4920477.
    28. Chang SJ, Bristow R. Reply to A Macrì. J Gynecol Oncol. 2015 Jul; 26(3):242. PMID: 26413600.
      View in: PubMed
    29. Grove N, Zheng M, Bristow R, Eskander RN. Extensive Tattoos Mimicking Lymphatic Metastasis on Positron Emission Tomography Scan in a Patient With Cervical Cancer. Obstet Gynecol. 2015 Jul; 126(1):182-5. PMID: 25923020.
      View in: PubMed
    30. Dottino JA, Cliby WA, Myers ER, Bristow R, Havrilesky LJ. Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. Gynecol Oncol. 2015 Sep; 138(3):694-9. PMID: 26072441.
      View in: PubMed
    31. LaFargue CJ, Bristow R. Transdiaphragmatic cardiophrenic lymph node resection for Stage IV ovarian cancer. Gynecol Oncol. 2015 Sep; 138(3):762-3. PMID: 26049122.
      View in: PubMed
    32. Hodeib M, Chang J, Liu F, Ziogas A, Dilley S, Randall LM, Anton-Culver H, Bristow R. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecol Oncol. 2015 Jul; 138(1):121-7. PMID: 25913132.
      View in: PubMed
    33. Chang SJ, Bristow R. Surgical technique of en bloc pelvic resection for advanced ovarian cancer. J Gynecol Oncol. 2015 Apr; 26(2):155. PMID: 25872895; PMCID: PMC4397232.
    34. Bristow R, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol. 2015 Apr; 125(4):833-42. PMID: 25751200.
      View in: PubMed
    35. Bristow R, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg. 2015 May; 220(5):940-50. PMID: 25840536.
      View in: PubMed
    36. Bristow R, Chang J, Ziogas A, Gillen DL, Bai L, Vieira VM. Spatial analysis of advanced-stage ovarian cancer mortality in California. Am J Obstet Gynecol. 2015 Jul; 213(1):43.e1-8. PMID: 25644440; PMCID: PMC4485540.
    37. Liu FW, Galvan-Turner VB, Pfaendler KS, Longoria TC, Bristow R. A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. Am J Obstet Gynecol. 2015 Jun; 212(6):717-24. PMID: 25582101; PMCID: PMC4457589.
    38. Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow R. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population. J Clin Oncol. 2014 Dec 20; 32(36):4113-9. PMID: 25385738; PMCID: PMC4517941.
    39. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow R. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015 Apr; 212(4):468.e1-9. PMID: 25448522.
      View in: PubMed
    40. Cliby WA, Powell MA, Al-Hammadi N, Chen L, Philip Miller J, Roland PY, Mutch DG, Bristow R. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol. 2015 Jan; 136(1):11-7. PMID: 25449311; PMCID: PMC4419829.
    41. Ménard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, Jaffray DA, Chung P, Brock KK, Haider MA. MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology. 2015 Jan; 274(1):181-91. PMID: 25203127.
      View in: PubMed
    42. Cripe J, Tseng J, Eskander R, Fader AN, Tanner E, Bristow R. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Ann Surg Oncol. 2015 Feb; 22(2):655-61. PMID: 25155402.
      View in: PubMed
    43. Krill LS, Adelson JW, Randall LM, Bristow R. Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer? Gynecol Oncol. 2014 Sep; 134(3):447-9. PMID: 24976631.
      View in: PubMed
    44. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):195-204. PMID: 24849582.
      View in: PubMed
    45. Bristow R, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol. 2014 Jul; 134(1):60-7. PMID: 24680770; PMCID: PMC4095874.
    46. Eskander RN, Cripe J, Bristow R. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise. Curr Treat Options Oncol. 2014 Mar; 15(1):27-40. PMID: 24338278.
      View in: PubMed
    47. Goodrich ST, Bristow R, Santoso JT, Miller RW, Smith A, Zhang Z, Ueland FR. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. Am J Obstet Gynecol. 2014 Jul; 211(1):65.e1-65.e11. PMID: 24530816.
      View in: PubMed
    48. Bristow R, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014 Feb; 132(2):403-10. PMID: 24361578.
      View in: PubMed
    49. Fader AN, Java J, Krivak TC, Bristow R, Tergas AI, Bookman MA, Armstrong DK, Tanner EJ, Gershenson DM. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. Gynecol Oncol. 2014 Mar; 132(3):560-5. PMID: 24333362.
      View in: PubMed
    50. Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow R, Diaz-Montes TP, Palermo R, Kurman RJ. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol. 2014 Jan; 132(1):33-7. PMID: 24316307.
      View in: PubMed
    51. Kong V, Rosewall T, Chen S, Craig T, Bristow R, Milosevic M, Kwan M, Chung P. Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):323-329. PMID: 25194101.
      View in: PubMed
    52. Bristow R. In reply. Obstet Gynecol. 2013 Oct; 122(4):907. PMID: 24084556.
      View in: PubMed
    53. Longoria TC, Ueland FR, Zhang Z, Chan DW, Smith A, Fung ET, Munroe DG, Bristow R. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol. 2014 Jan; 210(1):78.e1-9. PMID: 24055582.
      View in: PubMed
    54. Bristow R, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munroe DG, Ueland FR. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol. 2013 Dec; 209(6):581.e1-8. PMID: 23942039.
      View in: PubMed
    55. Fader AN, Java J, Ueda S, Bristow R, Armstrong DK, Bookman MA, Gershenson DM. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013 Aug; 122(2 Pt 1):225-32. PMID: 23969788; PMCID: PMC4870595.
    56. Chang SJ, Hodeib M, Chang J, Bristow R. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013 Sep; 130(3):493-8. PMID: 23747291.
      View in: PubMed
    57. Bristow R, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol. 2013 Jun; 121(6):1226-34. PMID: 23812456.
      View in: PubMed
    58. Naik R, Spirtos N, Pomel C, Bristow R, Chi D, Vergote I, Donovan J. The "definitive" trial of surgical cytoreduction in advanced-stage ovarian cancer. Int J Gynecol Cancer. 2013 May; 23(4):588-91. PMID: 23611959.
      View in: PubMed
    59. Alvarez RD, Gray HJ, Timmins PF, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow R, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. Gynecol Oncol. 2013 Apr; 129(1):3-4. PMID: 23638463.
      View in: PubMed
    60. Bristow R, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY, Mutch DG, Cliby WA. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst. 2013 Jun 05; 105(11):823-32. PMID: 23539755; PMCID: PMC3691950.
    61. Krill LS, Bristow R. Robotic surgery: gynecologic oncology. Cancer J. 2013 Mar-Apr; 19(2):167-76. PMID: 23528726.
      View in: PubMed
    62. Al Rawahi T, Lopes AD, Bristow R, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013 Feb 28; (2):CD008765. PMID: 23450588.
      View in: PubMed
    63. Chang SJ, Bristow R, Ryu HS. Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J Gynecol Oncol. 2013 Jan; 24(1):29-36. PMID: 23346311; PMCID: PMC3549504.
    64. Tergas AI, Tseng JH, Bristow R. Impact of race and ethnicity on treatment and survival of women with vulvar cancer in the United States. Gynecol Oncol. 2013 Apr; 129(1):154-8. PMID: 23274562.
      View in: PubMed
    65. Bristow R, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, Munroe DG. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013 Feb; 128(2):252-9. PMID: 23178277.
      View in: PubMed
    66. Foltz WD, Wu A, Chung P, Catton C, Bayley A, Milosevic M, Bristow R, Warde P, Simeonov A, Jaffray DA, Haider MA, Ménard C. Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. J Magn Reson Imaging. 2013 Apr; 37(4):909-16. PMID: 23097411.
      View in: PubMed
    67. Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, Narod SA, Nam RK. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst. 2012 Aug 22; 104(16):1260-2. PMID: 22781434.
      View in: PubMed
    68. Chang SJ, Bristow R, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012 Dec; 19(13):4059-67. PMID: 22766983.
      View in: PubMed
    69. Chang SJ, Bristow R, Ryu HS. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecol Oncol. 2012 Sep; 126(3):381-6. PMID: 22609747.
      View in: PubMed
    70. Peiretti M, Bristow R, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012 Aug; 126(2):220-3. PMID: 22555105.
      View in: PubMed
    71. Chang SJ, Bristow R, Ryu HS. A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer. Gynecol Oncol. 2012 Jul; 126(1):82-6. PMID: 22516661.
      View in: PubMed
    72. Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res. 2012 Apr 01; 18(7):2108-14. PMID: 22465832.
      View in: PubMed
    73. Salani R, Bristow R. Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar; 55(1):75-95. PMID: 22343231.
      View in: PubMed
    74. Chang SJ, Bristow R. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol. 2012 May; 125(2):483-92. PMID: 22366151.
      View in: PubMed
    75. Giuntoli RL, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, Bristow R. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer. 2012 Feb; 22(2):273-9. PMID: 22146771.
      View in: PubMed
    76. Cliby W, Aletti G, Chi D, Bristow R. Re: defining the limits of radical cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):509-10; author reply 508-9. PMID: 22266023.
      View in: PubMed
    77. Gunderson CC, Fader AN, Carson KA, Bristow R. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May; 125(2):477-82. PMID: 22245711.
      View in: PubMed
    78. Gardner GJ, Baser RE, Brady MF, Bristow R, Markman M, Spriggs D, Thaler HT. CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol. 2012 Feb; 124(2):216-20. PMID: 22033034.
      View in: PubMed
    79. Bristow R. "Kegel ball" induced vaginal cuff dehiscence following radical abdominal hysterectomy: laparoscopically-assisted transvaginal retrieval. Gynecol Oncol. 2012 Jan; 124(1):170. PMID: 21982045.
      View in: PubMed
    80. Chi DS, Bristow R, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol. 2011 Nov 01; 29(31):4073-5. PMID: 21931018.
      View in: PubMed
    81. Salani R, Nagel CI, Drennen E, Bristow R. Recurrence patterns and surveillance for patients with early stage endometrial cancer. Gynecol Oncol. 2011 Nov; 123(2):205-7. PMID: 21820709.
      View in: PubMed
    82. Lu D, Kuhn E, Bristow R, Giuntoli RL, Kjær SK, Shih IeM, Roden RB. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011 Sep; 122(3):560-6. PMID: 21704359; PMCID: PMC3152615.
    83. Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow R, Goff BA. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011 Jun; 204(6):466-78. PMID: 21752752.
      View in: PubMed
    84. Bristow R, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol. 2011 Aug; 122(2):319-23. PMID: 21632099.
      View in: PubMed
    85. Levinson KL, Bristow R, Donohue PK, Kanarek NF, Trimble CL. Impact of payer status on treatment of cervical cancer at a tertiary referral center. Gynecol Oncol. 2011 Aug; 122(2):324-7. PMID: 21620446; PMCID: PMC4612589.
    86. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow R. Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care. Laryngoscope. 2011 Apr; 121(4):746-52. PMID: 21433017; PMCID: PMC3612951.
    87. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow R. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug; 205(2):103-10. PMID: 21411052.
      View in: PubMed
    88. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow R. Volume-based trends in surgical care of patients with oropharyngeal cancer. Laryngoscope. 2011 Apr; 121(4):738-45. PMID: 21394725.
      View in: PubMed
    89. Bristow R, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol. 2011 May 01; 121(2):364-8. PMID: 21288564.
      View in: PubMed
    90. Gourin CG, Forastiere AA, Sanguineti G, Koch WM, Marur S, Bristow R. Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care. Laryngoscope. 2011 Jan; 121(1):85-90. PMID: 21181983.
      View in: PubMed
    91. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow R. Volume-based trends in laryngeal cancer surgery. Laryngoscope. 2011 Jan; 121(1):77-84. PMID: 21125633.
      View in: PubMed
    92. Krill LS, Ueda SM, Gerardi M, Bristow R. Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Gynecol Oncol. 2011 Feb; 120(2):220-3. PMID: 21145096.
      View in: PubMed
    93. Gourin CG, Tufano RP, Forastiere AA, Koch WM, Pawlik TM, Bristow R. Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1191-8. PMID: 21173367.
      View in: PubMed
    94. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow R, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011 Jan 01; 29(1):69-75. PMID: 21098323; PMCID: PMC3055861.
    95. Wahl RL, Javadi MS, Eslamy H, Shruti A, Bristow R. The Roles of Fluorodeoxyglucose-PET/Computed Tomography in Ovarian Cancer: Diagnosis, Assessing Response, and Detecting Recurrence. PET Clin. 2010 Oct; 5(4):447-61. PMID: 27157972.
      View in: PubMed
    96. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, Chi DS, Bristow R, Cliby WA. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011 Jan; 120(1):23-8. PMID: 20933255.
      View in: PubMed
    97. Bashir S, Gerardi MA, Giuntoli RL, Montes TP, Bristow R. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2010 Nov; 119(2):255-8. PMID: 20739051.
      View in: PubMed
    98. Barlin JN, Puri I, Bristow R. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010 Jul; 118(1):14-8. PMID: 20434198.
      View in: PubMed
    99. Bristow R, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010 Sep; 118(3):262-7. PMID: 20573392.
      View in: PubMed
    100. Galaal K, Naik R, Bristow R, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010 Jun 16; (6):CD007822. PMID: 20556785; PMCID: PMC4170993.
    101. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow R, Zhang H, Shih IeM. Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol. 2010; 2010:285191. PMID: 20508725; PMCID: PMC2873657.
    102. Barlin JN, Bristow R, Bleich K, Giuntoli RL, Thompson S, Diaz-Montes TP. Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study. Clin Imaging. 2010 May-Jun; 34(3):191-5. PMID: 20416483.
      View in: PubMed
    103. Barlin JN, Bristow R, Murillo AM, Zahurak M, Veras E, Salani R. Predictive value of endocervical curettage at cervical conization and provider practices in management of high-grade cervical dysplasia. J Reprod Med. 2010 Mar-Apr; 55(3-4):129-33. PMID: 20506673.
      View in: PubMed
    104. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow R. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010 May; 117(2):336-40. PMID: 20153027.
      View in: PubMed
    105. Ibeanu OA, Bristow R. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer. 2010 Jan; 20 Suppl 1:S1-11. PMID: 20065732.
      View in: PubMed
    106. Ueda SM, Mao TL, Kuhajda FP, Vasoontara C, Giuntoli RL, Bristow R, Kurman RJ, Shih IeM. Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93. Am J Pathol. 2009 Dec; 175(6):2618-24. PMID: 19893031; PMCID: PMC2789637.
    107. Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, Rosewall T, Warde PR, Catton CN. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol. 2009 Nov 03; 4:50. PMID: 19887007; PMCID: PMC2777178.
    108. Bristow R, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol. 2009 Dec; 115(3):334-8. PMID: 19766295.
      View in: PubMed
    109. Bristow R, Puri I, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Analysis of contemporary trends in access to high-volume ovarian cancer surgical care. Ann Surg Oncol. 2009 Dec; 16(12):3422-30. PMID: 19711131.
      View in: PubMed
    110. Bristow R. Advanced cytoreductive surgery in gynecologic oncology. Gynecol Oncol. 2009 Aug; 114(2 Suppl):S1-2. PMID: 19573698.
      View in: PubMed
    111. Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow R, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009 Aug; 29(8):2875-84. PMID: 19661290.
      View in: PubMed
    112. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow R, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009 Jul 20; 9:244. PMID: 19619303; PMCID: PMC2719664.
    113. Chi DS, Bristow R. In response to: Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol. 2009 Oct; 115(1):168-169. PMID: 30036930.
      View in: PubMed
    114. Barlin JN, Ueda SM, Bristow R. Cytoreductive surgery for advanced and recurrent endometrial cancer: a review of the literature. Womens Health (Lond). 2009 Jul; 5(4):403-11. PMID: 19586432.
      View in: PubMed
    115. Kratz KG, Santillan A, Gu M, Bristow R. Radical surgical cytoreduction of progressive leiomyomatosis peritonealis disseminata: a case report. J Reprod Med. 2009 Jul; 54(7):447-50. PMID: 19691262.
      View in: PubMed
    116. Bristow R, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, Giuntoli RL, Maggioni A. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009 Aug; 114(2):173-7. PMID: 19482344.
      View in: PubMed
    117. Tatsumi M, Cohade C, Bristow R, Wahl RL. Imaging uterine cervical cancer with FDG-PET/CT: direct comparison with PET. Mol Imaging Biol. 2009 Jul-Aug; 11(4):229-35. PMID: 19434463.
      View in: PubMed
    118. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow R, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W, Teng N. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):498-531. PMID: 19460278.
      View in: PubMed
    119. Tsai-Turton M, Santillan A, Lu D, Bristow R, Chan KC, Shih IeM, Roden RB. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009 Jul; 114(1):12-7. PMID: 19398128; PMCID: PMC2694938.
    120. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow R, Aghajanian C, Barakat RR. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009 Jul; 114(1):26-31. PMID: 19395008.
      View in: PubMed
    121. Levinson K, Nasaar H, Bristow R. Human chorionic gonadotropin production by a benign lung nodule. Int J Gynaecol Obstet. 2009 Jun; 105(3):263. PMID: 19249050.
      View in: PubMed
    122. Herzer KR, Rodriguez-Paz JM, Doyle PA, Flint PW, Feller-Kopman DJ, Herman J, Bristow R, Cover R, Pronovost PJ, Mark LJ. A practical framework for patient care teams to prospectively identify and mitigate clinical hazards. Jt Comm J Qual Patient Saf. 2009 Feb; 35(2):72-81. PMID: 19241727.
      View in: PubMed
    123. Bristow R. Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen. Gynecol Oncol. 2009 Jan; 112(1):1-3. PMID: 19100914.
      View in: PubMed
    124. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, Haile R, Hopper JL, LeMarchand L, Lindor N, Parfrey P, Potter J, Younghusband B, Gallinger S. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 2009 Apr; 136(4):1251-60. PMID: 19245865; PMCID: PMC2739726.
    125. Salani R, Puri I, Bristow R. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol. 2009 Feb; 200(2):182.e1-5. PMID: 19019325.
      View in: PubMed
    126. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow R, Mazitschek R, Bradner J, Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res. 2008 Nov 15; 14(22):7340-7. PMID: 19010849; PMCID: PMC2744414.
    127. Bristow R, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009 Jan; 112(1):265-74. PMID: 18937969.
      View in: PubMed
    128. Helm CW, Bristow R, Kusamura S, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008 Sep 15; 98(4):283-90. PMID: 18726895.
      View in: PubMed
    129. Tanner EJ, Zahurak ML, Bristow R, Díaz-Montes TP. Surgical care of young women diagnosed with ovarian cancer: a population-based perspective. Gynecol Oncol. 2008 Nov; 111(2):221-5. PMID: 18786718.
      View in: PubMed
    130. Rybak EA, Polotsky AJ, Woreta T, Hailpern SM, Bristow R. Explained compared with unexplained fever in postoperative myomectomy and hysterectomy patients. Obstet Gynecol. 2008 May; 111(5):1137-42. PMID: 18448746.
      View in: PubMed
    131. Santillan A, Govan L, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Bristow R. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice. Gynecol Oncol. 2008 Jun; 109(3):388-93. PMID: 18405946.
      View in: PubMed
    132. Bristow R, Peiretti M, Zanagnolo V, Salani R, Giuntoli RL, Maggioni A. Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol. 2008 Jun; 109(3):364-9. PMID: 18396322.
      View in: PubMed
    133. Judson K, McCormick C, Vang R, Yemelyanova AV, Wu LS, Bristow R, Ronnett BM. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol. 2008 Apr; 27(2):182-90. PMID: 18317225.
      View in: PubMed
    134. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow R. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2008 Feb; 108(2):271-5. PMID: 18164380.
      View in: PubMed
    135. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow R, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W, Teng N. Cervical cancer. J Natl Compr Canc Netw. 2008 Jan; 6(1):14-36. PMID: 18267056.
      View in: PubMed
    136. Gerardi MA, Santillan A, Meisner B, Zahurak ML, Diaz Montes TP, Giuntoli RL, Bristow R. A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers. Gynecol Oncol. 2008 Feb; 108(2):282-6. PMID: 18023851.
      View in: PubMed
    137. Salani R, Diaz-Montes T, Giuntoli RL, Bristow R. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007 Dec; 14(12):3552-7. PMID: 17896149.
      View in: PubMed
    138. Bazzaro M, Santillan A, Lin Z, Tang T, Lee MK, Bristow R, Shih IeM, Roden RB. Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol. 2007 Nov; 171(5):1640-9. PMID: 17872978; PMCID: PMC2043524.
    139. Salani R, Zahurak ML, Santillan A, Giuntoli RL, Bristow R. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007 Dec; 107(3):495-9. PMID: 17854870.
      View in: PubMed
    140. Díaz-Montes TP, Zahurak ML, Bristow R. Predictors of extended intensive care unit resource utilization following surgery for ovarian cancer. Gynecol Oncol. 2007 Dec; 107(3):464-8. PMID: 17765297.
      View in: PubMed
    141. Díaz-Montes TP, Zahurak ML, Giuntoli RL, Bristow R. Concentration of uterine cancer surgical care among the elderly: a population-based perspective. Gynecol Oncol. 2007 Dec; 107(3):436-40. PMID: 17764726.
      View in: PubMed
    142. Bristow R, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Meisner BC, Armstrong DK, Frick KD. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007 Sep; 106(3):476-81. PMID: 17688927.
      View in: PubMed
    143. Wheeler DT, Bristow R, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007 Jul; 31(7):988-98. PMID: 17592264.
      View in: PubMed
    144. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow R, Chi DS, Cliby WA. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007 Oct; 107(1):99-106. PMID: 17602726.
      View in: PubMed
    145. Giuntoli RL, Garrett-Mayer E, Bristow R, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007 Jul; 106(1):82-8. PMID: 17434579.
      View in: PubMed
    146. Bristow R, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL, Meisner BC, Frick KD, Armstrong DK. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer. 2007 Apr 15; 109(8):1513-22. PMID: 17354232.
      View in: PubMed
    147. McCormick CC, Giuntoli RL, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow R. The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol. 2007 Jun; 105(3):791-5. PMID: 17408727.
      View in: PubMed
    148. Salani R, Neuberger I, Kurman RJ, Bristow R, Chang HW, Wang TL, Shih IeM. Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol. 2007 Apr; 26(2):141-6. PMID: 17413980.
      View in: PubMed
    149. Armstrong DK, Bookman MA, McGuire W, Bristow R, Schilder JM. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jun; 105(3):667-71. PMID: 17368526; PMCID: PMC1987371.
    150. Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK, Bristow R. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007 Feb 15; 109(4):685-91. PMID: 17219441.
      View in: PubMed
    151. Axtell AE, Lee MH, Bristow R, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider CH. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007 Feb 01; 25(4):384-9. PMID: 17264334.
      View in: PubMed
    152. Bristow R, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007 Feb; 104(2):480-90. PMID: 17166564.
      View in: PubMed
    153. Santillan A, Karam AK, Li AJ, Giuntoli R, Gardner GJ, Cass I, Karlan BY, Bristow R. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007 Mar; 104(3):686-90. PMID: 17141302.
      View in: PubMed
    154. Warde P, Tsuji D, Bristow R. A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer. Clin Genitourin Cancer. 2006 Dec; 5(3):235-7. PMID: 17239279.
      View in: PubMed
    155. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow R, Morin PJ, Kurman RJ, Wang TL, Shih IeM. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A. 2006 Dec 05; 103(49):18739-44. PMID: 17130457; PMCID: PMC1693732.
    156. Bristow R, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL, Peeler ST. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol. 2007 Mar; 104(3):739-46. PMID: 17097723.
      View in: PubMed
    157. Diaz-Montes TP, Farinola MA, Zahurak ML, Bristow R, Rosenthal DL. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol. 2007 Feb; 104(2):366-71. PMID: 17049972.
      View in: PubMed
    158. Karam AK, Santillan A, Bristow R, Giuntoli R, Gardner GJ, Cass I, Karlan BY, Li AJ. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol. 2007 Feb; 104(2):377-80. PMID: 17014899.
      View in: PubMed
    159. Giuntoli RL, Vang RS, Bristow R. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol. 2006 Sep; 49(3):492-505. PMID: 16885656.
      View in: PubMed
    160. Díaz-Montes TP, Zahurak ML, Giuntoli RL, Gardner GJ, Bristow R. Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality. Gynecol Oncol. 2006 Dec; 103(3):1043-7. PMID: 16876234.
      View in: PubMed
    161. Bristow R, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006 Dec; 103(3):1070-6. PMID: 16875720.
      View in: PubMed
    162. Alphs HH, Zahurak ML, Bristow R, Díaz-Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol. 2006 Dec; 103(3):1048-53. PMID: 16876237.
      View in: PubMed
    163. Bristow R, Nugent AC, Zahurak ML, Khouzhami V, Fox HE. Impact of surgeon specialty on ovarian-conserving surgery in young females with an adnexal mass. J Adolesc Health. 2006 Sep; 39(3):411-6. PMID: 16919804.
      View in: PubMed
    164. Bristow R, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006 Nov; 103(2):709-13. PMID: 16797686.
      View in: PubMed
    165. Bristow R, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet. 2006 May 13; 367(9522):1558-60. PMID: 16698396.
      View in: PubMed
    166. Bristow R, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol. 2006 Oct; 103(1):281-7. PMID: 16631236.
      View in: PubMed
    167. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow R, Campos S, Cho KR, Copeland L, Eifel P, Jaggernauth W, Jhingran A, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan RJ, Nag S, Partridge EE, Powell CB, Remmenga SW, Reynolds RK, Small W, Soper J, Teng N. Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62. PMID: 16687093.
      View in: PubMed
    168. Bristow R. Predicting "unresectable" ovarian cancer: Taking aim at a moving target. Gynecol Oncol. 2006 Mar; 100(3):449-50. PMID: 16488272.
      View in: PubMed
    169. Santillan A, Bristow R. Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol. 2006 Feb; 3(2):108-12; quiz 1 p following 112. PMID: 16462852.
      View in: PubMed
    170. Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow R, Trimble EL, Warren JL. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst. 2006 Feb 01; 98(3):163-71. PMID: 16449676.
      View in: PubMed
    171. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow R, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006 Feb 01; 98(3):172-80. PMID: 16449677.
      View in: PubMed
    172. Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow R. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005 Dec 20; 23(36):9338-43. PMID: 16361633.
      View in: PubMed
    173. Díaz-Montes TP, Rosenthal LE, Bristow R, Grumbine FC. Primary insular carcinoid of the ovary. Gynecol Oncol. 2006 Apr; 101(1):175-8. PMID: 16298421.
      View in: PubMed
    174. Garg R, Zahurak ML, Trimble EL, Armstrong DK, Bristow R. Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol. 2005 Oct; 99(1):65-70. PMID: 15979132.
      View in: PubMed
    175. Díaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow R. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol. 2006 Jan; 100(1):139-44. PMID: 16182348.
      View in: PubMed
    176. Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow R, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39):14004-9. PMID: 16172393; PMCID: PMC1236547.
    177. Díaz-Montes TP, Jacene HA, Wahl RL, Bristow R. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol. 2005 Sep; 98(3):510-2. PMID: 15992914.
      View in: PubMed
    178. Bristow R, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005 Nov; 99(2):301-8. PMID: 16085295.
      View in: PubMed
    179. Díaz-Montes TP, Zahurak ML, Giuntoli RL, Gardner GJ, Gordon TA, Armstrong DK, Bristow R. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005 Nov; 99(2):352-7. PMID: 16055176.
      View in: PubMed
    180. Bristow R, Giuntoli RL, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol. 2005 Nov; 99(2):294-300. PMID: 16051330.
      View in: PubMed
    181. Kim YW, Srodon M, Bristow R. Stage IV micropapillary serous ovarian carcinoma: a report of three cases. Int J Gynecol Pathol. 2005 Jul; 24(3):235-8. PMID: 15968198.
      View in: PubMed
    182. Díaz-Montes TP, Alberg A, Zahurak ML, Trimble EL, Bristow R. Cancer of the uterine corpus among Hispanic women living in the United States: patterns of staging, diagnosis, and primary treatment. Gynecol Oncol. 2005 Mar; 96(3):753-9. PMID: 15721422.
      View in: PubMed
    183. Simpkins F, Zahurak M, Armstrong D, Grumbine F, Bristow R. Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol. 2005 Mar; 105(3):507-13. PMID: 15738016.
      View in: PubMed
    184. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IeM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 2005 Mar 01; 65(5):1994-2000. PMID: 15753399.
      View in: PubMed
    185. Teng N, Abu-Rustum NR, Bahador A, Bookman MA, Bristow R, Campos S, Cho KR, Copeland L, Eifel P, Fiorica J, Greer BE, Kapp DS, Kavanagh J, Koh WJ, Kuettel M, Lurain JR, Molpus KL, Nag S, Partridge EE, Powell CB, Reynolds RK, Small W, Soper J, Tillmanns TD. Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):612-30. PMID: 19780304.
      View in: PubMed
    186. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 2004 Oct 01; 10(19):6432-6. PMID: 15475429.
      View in: PubMed
    187. Giuntoli RL, Bristow R. Uterine leiomyosarcoma: present management. Curr Opin Oncol. 2004 Jul; 16(4):324-7. PMID: 15187886.
      View in: PubMed
    188. Bristow R. Secondary cytoreductive surgery for isolated nodal recurrence of ovarian cancer. Ann Surg Oncol. 2004 Jul; 11(7):639-40. PMID: 15197010.
      View in: PubMed
    189. Wolfberg AJ, Montz FJ, Bristow R. Role of obesity in the surgical management of advanced-stage ovarian cancer. J Reprod Med. 2004 Jun; 49(6):473-6. PMID: 15283057.
      View in: PubMed
    190. Bristow R, Zahurak ML, del Carmen MG, Gordon TA, Fox HE, Trimble EL, Montz FJ. Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol. 2004 May; 93(2):353-60. PMID: 15099945.
      View in: PubMed
    191. Pannu HK, Bristow R, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics. 2004 Jan-Feb; 24(1):209-23. PMID: 14730047.
      View in: PubMed
    192. Del Carmen MG, Smith Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow R. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer. 2003 Oct 15; 98(8):1658-63. PMID: 14534882.
      View in: PubMed
    193. Bristow R, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg. 2003 Oct; 197(4):565-74. PMID: 14522325.
      View in: PubMed
    194. Bristow R, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, Wahl RL, Montz FJ. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003 Sep; 90(3):519-28. PMID: 13678719.
      View in: PubMed
    195. Karam AK, Bristow R, Bienstock J, Montz FJ. Argon beam coagulation facilitates management of placenta percreta with bladder invasion. Obstet Gynecol. 2003 Sep; 102(3):555-6. PMID: 12962942.
      View in: PubMed
    196. Lambrou NC, Bristow R. Ovarian cancer in elderly women. Oncology (Williston Park). 2003 Aug; 17(8):1075-81; discussion 1081, 1085-6, 1091. PMID: 12966676.
      View in: PubMed
    197. Wang BG, Huang HY, Chen YC, Bristow R, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IeM. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003 Jul 15; 63(14):3966-8. PMID: 12873992.
      View in: PubMed
    198. Pannu HK, Bristow R, Montz FJ, Fishman EK. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics. 2003 May-Jun; 23(3):687-701. PMID: 12740470.
      View in: PubMed
    199. Ward RM, Bristow R. Cancer and pregnancy: recent developments. Curr Opin Obstet Gynecol. 2002 Dec; 14(6):613-7. PMID: 12441701.
      View in: PubMed
    200. Bristow R, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Recurrent micropapillary serous ovarian carcinoma. Cancer. 2002 Aug 15; 95(4):791-800. PMID: 12209723.
      View in: PubMed
    201. Huh JJ, Montz FJ, Bristow R. Struma ovarii associated with pseudo-Meigs' syndrome and elevated serum CA 125. Gynecol Oncol. 2002 Aug; 86(2):231-4. PMID: 12144834.
      View in: PubMed
    202. Bristow R, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol. 2002 Aug; 86(2):163-70. PMID: 12144823.
      View in: PubMed
    203. Gossett DR, Montz FJ, Bristow R. Cystic paracervical mass as an unusual sequela of graft-versus-host disease. A case report. J Reprod Med. 2002 Jul; 47(7):600-2. PMID: 12170542.
      View in: PubMed
    204. Cornelison TL, Montz FJ, Bristow R, Chou B, Bovicelli A, Zeger SL. Decreased incidence of cervical cancer in medicare-eligible California women. Obstet Gynecol. 2002 Jul; 100(1):79-86. PMID: 12100807.
      View in: PubMed
    205. Bristow R, Simpkins F, Pannu HK, Fishman EK, Montz FJ. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol. 2002 Apr; 85(1):196-200. PMID: 11925145.
      View in: PubMed
    206. Montz FJ, Bristow R, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002 Apr; 186(4):651-7. PMID: 11967486.
      View in: PubMed
    207. Becker SO, Tomacruz R, Kaufman HS, Bristow R, Montz FJ. Gynecologic abnormalities in surgically treated women with stage II or III rectal cancer. J Am Coll Surg. 2002 Mar; 194(3):315-23. PMID: 11893135.
      View in: PubMed
    208. Bristow R, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 01; 20(5):1248-59. PMID: 11870167.
      View in: PubMed